Story

Hims & Hers Lifts Full-Year Revenue Forecast on Strong Subscriber Growth

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
Hims & Hers Lifts Full-Year Revenue Forecast on Strong Subscriber Growth
Text size
Background

Hims & Hers Health on Monday raised its full-year revenue forecast and reported second-quarter results that surpassed estimates, driven by a significant increase in subscribers for its telehealth platform and personalized healthcare offerings.

Upgraded Outlook and Key Metrics

The company now projects annual revenue in the range of $3.1 billion to $3.3 billion, an increase from its previous guidance of $2.8 billion to $3 billion. The optimistic outlook follows a strong second quarter that saw its subscriber base grow 19% year-over-year to nearly 2.9 million.

Key performance indicators from the second quarter include:

  • Subscribers: Increased to nearly 2.9 million, up 19% from a year earlier.
  • Revenue per Subscriber: Monthly online revenue per average subscriber climbed 21% to $92.

"We expect our domestic business to continue accelerating through the second half of the year," said Yemi Okupe, the company's chief financial officer.

Sample IUX Markets – In-articleAd

Strategic Shift Impacts Margins

While top-line growth accelerated, the company's profitability was impacted by a strategic pivot in its weight-loss category. Hims & Hers reported a second-quarter gross margin of 64%, a notable decrease from 76% in the same period last year.

The company attributed the margin compression to its move away from lower-cost compounded GLP-1 treatments toward offering branded, FDA-approved weight-loss drugs, such as Novo Nordisk's Wegovy. This transition, which followed a partnership with Novo Nordisk announced in March, resulted in restructuring costs of about $33 million. Hims & Hers has previously stated it expects to return to profitability in 2027.

Market Reaction

Despite the strong revenue forecast, shares of Hims & Hers were down 1.3% in volatile after-market trading. The market's reaction suggests investors are weighing the company's robust growth against the near-term costs and margin pressures associated with its new strategy in the lucrative weight-loss market.

Read next

More on Stocks
Back to latest news

LATEST